{"ticker": {"uuid": "345e29c8-fcd5-4afe-a7a8-3278f432ac10", "symbol": "NERV", "name": "Minerva Neurosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neurosciences Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOck5rbUwzWnA3c3BMclRNYnJYcG9tanVxU3dBNDFkNXpKMU4zNHFUcmRHUU9ISDBLT3otRkxOQWJhTnM3SjlTS0x3Zy1RdTdSOExGd0h3blFSYkNPdUhfMmlxa3VvSzR0eFlXdWJzdUNDMVFmbzc1RnY1S0tqdUZQSWRiVUtHdFdxanlJNF9RQi1POHgzVndaSGZPZENLRGtsUDQtdjJWRE00VUFocm05WEEzdW5Idw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T01:05:22+00:00", "published_display": "15 Jul 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Federated Hermes reports 17.17% stake in Minerva (NASDAQ: NERV)", "summary": "Federated Hermes, Inc. has filed an Amendment No. 1 to a Schedule 13G/A, disclosing an ownership of 8,690,926 shares of Minerva Neurosciences, Inc. common stock, which represents a 17.17% stake. The filing includes related reporting persons such as the Voting Shares Irrevocable T", "url": "https://www.stocktitan.net/sec-filings/NERV/schedule-13g-a-minerva-neurosciences-inc-amended-passive-investment-d-766c7b00e7ed.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:40:07", "published_display": "08 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) Slides 3.15% as Stock Tests Key Support at $4.52 - Iron Condor Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxORXJrd1RzejJMLTFvU2lJeDRRaFlmang3cU8zSHVwWGdDcElia0dIUzE0eFBROXMwVldjNUpRUE9uTGZ5akY1ZVJuV2ZWQk1sTlpYSDFGR3VZNms5T1dENlZzX1Z5NnN2SXkzWVcxTFNxUWlJV1MxMmZjOEZZN2J1X25faWQ2UG01VTQ1Z2ktcEhJSXdkb09mTTdhZHRwSFJWUVdJaFRIMmxVR2FIbjd3RHhlSQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T17:36:45+00:00", "published_display": "07 Jul 2026 17:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NERV - Minerva Neurosciences Inc Options", "summary": "This article provides a detailed financial overview of Minerva Neurosciences Inc. (NERV), including its stock performance, market capitalization, key financial ratios, and insider transaction data. It highlights various metrics such as EPS, sales, volatility, and analyst recommen", "url": "https://finviz.com/stock?t=NERV&p=w&ty=oc&b=2", "source_name": "Finviz", "published_at": "2026-07-03T05:40:13", "published_display": "03 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Dynamic Index", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company focused on central nervous system diseases, has been added to the Russell 2000 Dynamic Index. This inclusion is part of several other Russell index additions announced on June 29th and 28th, ", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-2000-dynamic-index-ce7f5fdddb8cf624?utm_source=copy&utm_medium=social&utm_campaign=share", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T20:40:34", "published_display": "30 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Small Cap Comp Value Benchmark", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV) has been added to the Russell Small Cap Comp Value Benchmark. This update reflects the company's inclusion in important market indices, alongside several other Russell index inclusions announced on the same day. Minerva Neurosciences i", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfde8ef723", "source_name": "marketscreener.com", "published_at": "2026-06-29T16:39:34", "published_display": "29 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPSll0ZHlVRVpfLTJXZk9kdXcxOGFValIwcWFFVWVuRWJMQ2pDVkc4cFBjYm5wWnlPN0pCb0N3WGFVWmQ2bTAxY2F0STlsYTdhdzBRZmJOWnlYVFNCak0xWGtTRXh1amV2NE14NjNkaHNZT0ZDZWNBSFdkd01zZEJjZGlnTjJkMWV2aUdQRzVpUEIwN3NFUDhjTF9qSlZRZ0Z0UjZTX3BQWEVzWnFmdG04NnJ4M0EyUFVUZkJicnBkVUpqX0w1TkJlQkhxMA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000E Index", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company, has been added to the Russell 3000E Index. The company focuses on developing product candidates for central nervous system (CNS) diseases, including roluperidone for schizophrenia and MIN-30", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-3000e-index-ce7f5fdedd8ff023", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:41:36", "published_display": "29 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000 Index", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company, has been added to the Russell 3000 Index. The news, published on June 28, 2026, highlights the company's progress in developing therapies for central nervous system diseases. Minerva Neurosc", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-3000-index-ce7f5fdfdf8bf220", "source_name": "marketscreener.com", "published_at": "2026-06-29T03:39:03", "published_display": "29 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Value Benchmark", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company focused on CNS diseases, has been added to the Russell 2500 Value Benchmark. The company is currently developing roluperidone for schizophrenia and has rights to MIN-301 for Parkinson's disea", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-2500-value-benchmark-ce7f5fdfde89f620", "source_name": "marketscreener.com", "published_at": "2026-06-29T03:39:03", "published_display": "29 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000 Value Benchmark", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV) has been added to the Russell 3000 Value Benchmark, according to an announcement published on June 28, 2026. This inclusion indicates an updated valuation and categorization within the financial markets. The company, a clinical-stage b", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-3000-value-benchmark-ce7f5fdcd08df72d?utm_source=copy&utm_medium=social&utm_campaign=share", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T19:39:42", "published_display": "28 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Minerva Neurosciences, Inc \u2013 NASDAQ:NERV", "summary": "This article provides a financial snapshot for Minerva Neurosciences, Inc (NASDAQ: NERV), specifically highlighting its price-to-sales forward ratio. It also details navigation and product information for the TradingView platform where this data is presented. The content appears ", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:39:54", "published_display": "28 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Growth Benchmark Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxOaTN3b2hqOXJ2Wk1JT3BKUVg3LVBiSDczZXBiWVdTU2hvSVhPa29iWTR1MUFFUnBuOXF2VW4wNTVNUVc2dDNFM1QxNnlwT205VjR2R181ck5zNGhRd21oY2VSWnk4eVFPT0dFd2NQNWVxWDctdWViNTR0TkRncnBteUp5UE1JM1R0OGh4WjItc0EwSzNHWF82NzZEVUZ4UnRyT0p4RHhpNk5taHN5dGlxTzB4aUhmTktqVVdPMFhtaGpodURoMHpjM0JqQUtrN29QUTN1bmlDd2FTZ1VpSElvMW9Md1hSUFhvazRxVUNHVnktamVsZDZzMFpPSFNBWnpnTHFwOXAwVE9Lc0NLOUM2WElrNWZQQ3BmNnJwX1pzWQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOREpQNnFWZzdNVEJJVTlhQVB5WjhLa1JRd255QlR5MDFZODRxemtfLXJsbF9sVVpBc0FtcVVqa3RvSmtXQW5BME1kYjc5ZlpoUkZIdmhIejA4MVlBZmJFZnVnZmhQc2RHMTRtRXRXLWdjYUJUcmFuNy0xR3FvVDdwaXNvaWNITm5lTk05Y1FQYUFXeU1xeTlLNnNxazl2MlluMk1wM3NBRFpZUVdSVGJucEJYX0JOcE5lWWluUmIyLXdWWVQtZWFJQnA1Zw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc Actuals & Estimates (NASDAQ:NERV)", "summary": "This article provides an overview of Minerva Neurosciences, Inc. (NASDAQ: NERV) stock, covering its current price, historical performance, analyst forecasts, and financial data. It details recent movements in stock price, market capitalization, and upcoming earnings report, along", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:39", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NERV Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Minerva Neurosciences, Inc. (NERV) stock, including analyst price targets, historical performance, and financial data. Analysts estimate a maximum future price of $14.00 and a minimum of $7.00 for NERV. The company's current stock price is $4.", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T01:05:46", "published_display": "27 Jun 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc Actuals & Estimates (FWB:4MNA)", "summary": "This article provides an overview of Minerva Neurosciences Inc (FWB:4MNA) stock, including its financial actuals, analyst estimates, price forecasts, and historical price performance. It details the company's past earnings and revenue, future earnings report dates, and states tha", "url": "https://www.tradingview.com/symbols/FWB-4MNA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:10:46", "published_display": "26 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Minerva Neurosciences Inc Stocks", "summary": "This article lists ETFs that invest in Minerva Neurosciences Inc (NERV) stocks, providing details such as market value, weight, issuer, and expense ratio for each fund. It highlights the Invesco NASDAQ Future Gen 200 ETF (QQQS) as one such fund, making investing in NERV more acce", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/etfs/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-06-26T09:10:23", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Minerva Neurosciences, Inc \u2013 NASDAQ:NERV", "summary": "This article provides a brief snapshot of the \"Price to earnings forward\" metric for Minerva Neurosciences, Inc (NASDAQ: NERV) on TradingView. It indicates that the market was closed with no trades at the time of publication. The content also lists various features and financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:23", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Minerva Neurosciences, Inc \u2013 NASDAQ:NERV", "summary": "This article provides financial data for Minerva Neurosciences, Inc. (NASDAQ: NERV), specifically focusing on its forward price-to-book ratio. The content is presented within the TradingView platform, indicating it's a financial data point rather than a detailed news analysis.", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:46", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4MNA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Minerva Neurosciences Inc. (4MNA) stock, including analyst price targets, historical highs and lows, and upcoming earnings information. Analysts have given a 1-year price forecast up to 8.16 EUR, with a maximum estimate of 12.03 EUR and a mini", "url": "https://www.tradingview.com/symbols/SWB-4MNA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:09:51", "published_display": "25 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc (NERV) Institutional Confidence", "summary": "Minerva Neurosciences Inc (NERV) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 275.59% quarter-over-quarter to 71.95%. The largest institutional shar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nerv/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:16", "published_display": "18 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc (NERV) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Minerva Neurosciences Inc (NERV) has an earnings forecast score of 6.67, ranking 324 out of 388 in its industry, with an average analyst price target of USD 4.50. Three analysts currently rate the stock as \"Hold.\" Despite a previous quarter's EPS of -25.45, the next quarter expec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nerv/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:16", "published_display": "18 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc (NERV) Valuation: PE, PB & Fair Value Analysis", "summary": "Minerva Neurosciences Inc (NERV) currently has a valuation score of 8.70, placing it 102nd out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -0.11, significantly below its recent high and above its recent low. However, releva", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nerv/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:16", "published_display": "18 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc (NERV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Minerva Neurosciences Inc (NERV), focusing on its current stock price momentum, support and resistance levels, and key indicators. It highlights NERV's momentum score, its trading range, and a predominantly \"Sell\" signal based on vari", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nerv/technical", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:16", "published_display": "18 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (Nasdaq:NERV) - Stock Analysis", "summary": "Minerva Neurosciences (Nasdaq:NERV) is a clinical-stage biopharmaceutical company focused on central nervous system diseases, with its lead product candidate roluperidone in a Phase 3 confirmatory trial for negative symptoms of schizophrenia. The company faces significant risks i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nerv/minerva-neurosciences", "source_name": "Simply Wall Street", "published_at": "2026-06-08T07:09:11", "published_display": "08 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) CFO awarded 680,000 stock options at $4.6800", "summary": "Minerva Neurosciences' SVP, CFO, and Secretary, Frederick W. Ahlholm, was granted 680,000 employee stock options with an exercise price of $4.6800 per share, expiring on June 2, 2036. The options will vest 25% on June 3, 2027, with the remainder vesting in equal quarterly install", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-ea31a3d5099f.html", "source_name": "Stock Titan", "published_at": "2026-06-06T05:09:53", "published_display": "06 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences grants 50,000 options to director | NERV Insider Trading", "summary": "Minerva Neurosciences (NERV) director Inderjit Kaul was granted 50,000 stock options as equity compensation. The options have an exercise price of $4.68 per share and vest in four equal quarterly installments, beginning three months after June 3, 2026. Following this grant, Kaul ", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-d1142b17194d.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:40:19", "published_display": "05 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences director granted 50,000 options | NERV Insider Trading", "summary": "Minerva Neurosciences director G Jan Van Heek was granted 50,000 stock options with an exercise price of $4.68 per share, expiring on June 2, 2036. The options will vest in four equal quarterly installments, contingent on his continued service as a non-employee director. This tra", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-42a119fcdce0.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:40:18", "published_display": "05 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) grants director 50,000 stock options at $4.68", "summary": "Minerva Neurosciences (NERV) has granted director Fouzia Laghrissi-Thode 50,000 stock options with an exercise price of $4.68 per share. The options expire on June 2, 2036, and vest in four equal quarterly installments, contingent on her continued service as a non-employee direct", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-66e71b36737a.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:40:18", "published_display": "05 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) awards 50,000 stock options to director", "summary": "Minerva Neurosciences (NERV) has granted 50,000 stock options to director Hans Peter Hasler with an exercise price of $4.68 per share and an expiration date of June 2, 2036. The options will vest in four equal quarterly installments, contingent on his continued service as a non-e", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-c1d1689ea12c.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:40:18", "published_display": "05 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NERV: Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027", "summary": "Minerva Neurosciences (NERV) is developing Roluperidone as a monotherapy for primary negative symptoms in schizophrenia. The drug is currently in a robust Phase III trial, with key efficacy data anticipated in 2027. This program is strengthened by strong intellectual property and", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3480925:0-nerv-roluperidone-targets-negative-symptoms-in-schizophrenia-with-pivotal-data-expected-in-2027/", "source_name": "TradingView", "published_at": "2026-06-04T23:38:59", "published_display": "04 Jun 2026 23:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) holders approve officer shield, drop forum clause", "summary": "Minerva Neurosciences (NERV) stockholders approved significant amendments to the company's charter and bylaws at their 2026 annual meeting. Key changes include limiting officers' monetary liability as permitted by Delaware law and removing the exclusive forum provision. Stockhold", "url": "https://www.stocktitan.net/sec-filings/NERV/8-k-minerva-neurosciences-inc-reports-material-event-658c9fbabf88.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:58", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/minerva-neurosciences-establishes-scientific-advisory-200500434.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:05:00+00:00", "published_display": "01 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Establishes Scientific Advisory Board", "summary": "Minerva Neurosciences has formed a Scientific Advisory Board (SAB) to guide the development of roluperidone for negative symptoms of schizophrenia and its broader R&D pipeline. The SAB comprises distinguished experts in psychiatry and neuroscience. Roluperidone is currently in a ", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304700/0/en/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:10:07", "published_display": "01 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/know-minerva-neurosciences-nerv-rating-160003876.html", "source_name": "Zacks", "published_at": "2026-05-20T16:00:03+00:00", "published_display": "20 May 2026 16:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/minerva-neurosciences-nerv-loses-37-133503465.html", "source_name": "Zacks", "published_at": "2026-05-20T13:35:03+00:00", "published_display": "20 May 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Minerva Neurosciences (NERV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5Fbjd4bEREQlkzMWtqNlEtLUwxZGFhM2VJQTQ3TmtHS0psVWRZUmRGcWpNSDJETHRXWjhMY3pjUGlUREFCSFo5LU1MVTNvRml3MmM3SlhhRWdWeDZxNHZrTkphU19hT0o0a21ZbA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/minerva-neurosciences-participate-2026-jefferies-200500719.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T20:05:00+00:00", "published_display": "18 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva CEO to join Jefferies 2026 healthcare fireside chat June 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVy0tNElXZ0FVZ3ZsODREUmk3SjU2RVM4R1diWUxvd3dSQnZHekkzMXdqR21jRzByc0UzMlFoN1ZnS0lmLXQ2TWh3SWwzdTFhYm5fLUpwSHQ3YUxTNzduZFpTTkxFcmZ4LWZXN0F0T0tmOHJJRHJrWUdEODJ0MXZYWVZzYjJpdU02SlR2RGViZ0x4Nm1rUmRRY3l4SkpaOEFuUGRhZWFwdmFwXzJ0blI5MnRSbmZzMk02djNOSg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Minerva Neurosciences: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/minerva-neurosciences-q1-earnings-snapshot-120758716.html", "source_name": "Associated Press", "published_at": "2026-05-05T12:07:58+00:00", "published_display": "05 May 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNc1JMMHdUQTR5WE1GSGxwaFdnS3pJTU9LRGdtTkYtd2NmT0N3Y01jNURYVEtMb09kazlvZE83bHE1S2xfc0p5Si16OG1NTmFsZmU4MUJEanZGSEl6TTRxdjVOUDNvWldYUFF5MWpvTzc4LTVaLWRzR3I2c0RXZFRkUDhQa3dmb2NMaHFlZ2YzYzhVeXBEWUM4ZWF1WVE2VTAyU0VMTUUwcEpheDh3eW5nbWZfT096Zw?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Minerva stock wins New Outperform at Citizens (NERV:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPMm5YXzRTYzA5OEl3YnJnLUZxenFtYUdYanJ4eHlNZXhFd0JNSmQ5Z29acmhjbHdhTkpYb0lKYnV2Mlc0cjUzbFhVUDl0UmpIbUZmS1VZR28yODhrYWMwM2ZOM2s3V19ZWjhMTmQxcHBaZWxIay03QVNmYUs2NHRyS0dmTVEtWUk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Announces First Patient Screened in", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wJBVV95cUxPN0hrN0JFQi11UEZMOUdmWjNUcjZfYmxBVEc5TUdIZEl5OG41TjBvb1JmT2lNamEwLTNzNHltb0ZCaDFZVjlTWDZjbnItNnEyQVp5NVdmZlk4c1oxYUZYSklJeG1PaHJVLW9QdlJoMEZsZUJJYmc0b29kbTNucXZ5c2JGVXIwaHItNkN3MnZfYm5GZU5KVTNIQ0JIUGMxQ05CU0VBNjJCb3BabE5aT3dhMzdsRm5QOEFZQkNybEE1NllZQWlpdXVfaTE4VHV4Sm9SRVdMN3BoN3lUMUZ5YkpyVlpHbGtlbDRfdmxJRWdOT2g2bXI5eUdYbmhCb1F3SVBqZ2xsZVJSb1NmekprQ185N3pQaU5CRS1oUG9tMk1vQTJkTEg1MGVlMzJTbmhtaXRxMG83YVZfWmhYMTN5Q3R1Rll0bE40THdMS0tycVp0a2pPSnJ1RXRTbjFfYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPY3pWYTZyVnJIYlcwdDkzLU1aUWFVWFVUamZzLTF0Y1l6a04xaW9mWFpkc1Jyc3ZBZFpFYXFqQ2h2VlFTNDV1RjNjUmRNcmR2MGRMT3VubGxRNWllVjNGRDlmNjVXcmpMbWtScjlFQmlMRTBscjBBdEVWenFJY0lwZjdBeWJnQThYMHMwcHJSQ1JrQzhT?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences\u2019 Unexpected Surge: Should You Invest?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOT1RqcnNBZ2dHMVp1Vk9JNVVhNTFGRl9CU3M5VVhFT2pXS2ZYMk8yZkFONTVEMWk4Qzg4c2s3elV0TFBWYTVaQnR0QkxCSWlRdVZqcTU1bGRwU0NYN2huMi1rbjNsNTh3NlJlZF9INjNGSGlyMk0ySThsUWxQZDhvYVB6VjE?oc=5", "source_name": "StocksToTrade", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Stock (NERV) Opinions on $200M Funding Deal | NERV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPVVBERVRCVXdmSWtLV3pGNXNwRkpUa3ZVcnZBUUcxaXN3Ty1UMFllelVvd3EzWlBxRVNSS2diLU9ndjZBRTgyT3gxLU5OTW9TQkVoY3JBUGVDdkVNODhlOGdKVDVxR3FkV3lXU0NmZmE0X2tUb2xVakQtbktDVk1MUWtqS1ZGSXY5dzdYbkRYSW9KUjZvV0o2YTdaaEJvTjN5R1pLUGNqZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Pr", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPN3U5M2p5Sm4tbTl5WFFrcjloUlFRYjFKMkd5RHdnY253dkVWQWR6M21QdmFHX3ZPTFkyV2dXOE00cDk0ZGVTRUN0enZGWjEtQzR2MDRXcmVoVHdpY0l6Z0Z5dlJId3ZKNF9JU1FpM0xJOEZ2N0Q5SGh2b19SRGlJTF84QUF5S0QwNVZFTkpuMG1Fc0p2d2c?oc=5", "source_name": "Market source", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosci (NERV) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5RTi1qRVJ6cTZGaUNJOGRBSXhfR0pEdm4zTmcwZWVybk03UmE2YmVIbWdyM2EwdGE5WGxILXhJMDROXzF6ano2T1otRmlYSGllNEZv?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:36:48+00:00", "published_display": "25 Apr 2025 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA hands Minerva Neurosciences refusal to file letter for its roluperidone NDA for schizophrenia", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPZGRBVGpLdWEzY2NJb09pTnRkOXdQcFdOY25nNEFLYVBnY0xNc0k5eE43aExDT1pZQVFsM0FiZXkwQ3lDcEV0RGVTOUpMMHR1a1ZNWEZaMzZ3MFRQZVZEUjJLcnVTRzV4Ml9XbEFBU0VXeWJyazlVMS1EUzZQY3ZoT3pOa2JDU2hqLWVVUzZ5RnA4cTZmS0xyZ0g0Q2d6SVBKX0sxbTZNQU92UXpZRGxmMm9NTmd1cGhTdnhDSXNONzQtZ2M2MlpmOGlpeDJJWEU?oc=5", "source_name": "drugdiscoverytrends.com", "published_at": "2022-10-20T07:00:00+00:00", "published_display": "20 Oct 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) Stock Price, News & Analysis $NERV", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE80XzJnYTlkN050MjZmUXFZUjR0aEMxYnM0bHlhUHFBQ3RHV3RnRkxHTldfMkw3MlhEQTJtY2JiTE9LOXd3eUNrVXlvQ2tLdktaM25MSGx5T0VsZw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-15T02:11:50+00:00", "published_display": "15 Aug 2016 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neurosciences Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOck5rbUwzWnA3c3BMclRNYnJYcG9tanVxU3dBNDFkNXpKMU4zNHFUcmRHUU9ISDBLT3otRkxOQWJhTnM3SjlTS0x3Zy1RdTdSOExGd0h3blFSYkNPdUhfMmlxa3VvSzR0eFlXdWJzdUNDMVFmbzc1RnY1S0tqdUZQSWRiVUtHdFdxanlJNF9RQi1POHgzVndaSGZPZENLRGtsUDQtdjJWRE00VUFocm05WEEzdW5Idw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T01:05:22+00:00", "published_display": "15 Jul 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federated Hermes reports 17.17% stake in Minerva (NASDAQ: NERV)", "summary": "Federated Hermes, Inc. has filed an Amendment No. 1 to a Schedule 13G/A, disclosing an ownership of 8,690,926 shares of Minerva Neurosciences, Inc. common stock, which represents a 17.17% stake. The filing includes related reporting persons such as the Voting Shares Irrevocable T", "url": "https://www.stocktitan.net/sec-filings/NERV/schedule-13g-a-minerva-neurosciences-inc-amended-passive-investment-d-766c7b00e7ed.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:40:07", "published_display": "08 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) Slides 3.15% as Stock Tests Key Support at $4.52 - Iron Condor Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxORXJrd1RzejJMLTFvU2lJeDRRaFlmang3cU8zSHVwWGdDcElia0dIUzE0eFBROXMwVldjNUpRUE9uTGZ5akY1ZVJuV2ZWQk1sTlpYSDFGR3VZNms5T1dENlZzX1Z5NnN2SXkzWVcxTFNxUWlJV1MxMmZjOEZZN2J1X25faWQ2UG01VTQ1Z2ktcEhJSXdkb09mTTdhZHRwSFJWUVdJaFRIMmxVR2FIbjd3RHhlSQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T17:36:45+00:00", "published_display": "07 Jul 2026 17:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NERV - Minerva Neurosciences Inc Options", "summary": "This article provides a detailed financial overview of Minerva Neurosciences Inc. (NERV), including its stock performance, market capitalization, key financial ratios, and insider transaction data. It highlights various metrics such as EPS, sales, volatility, and analyst recommen", "url": "https://finviz.com/stock?t=NERV&p=w&ty=oc&b=2", "source_name": "Finviz", "published_at": "2026-07-03T05:40:13", "published_display": "03 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Dynamic Index", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company focused on central nervous system diseases, has been added to the Russell 2000 Dynamic Index. This inclusion is part of several other Russell index additions announced on June 29th and 28th, ", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-2000-dynamic-index-ce7f5fdddb8cf624?utm_source=copy&utm_medium=social&utm_campaign=share", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T20:40:34", "published_display": "30 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Small Cap Comp Value Benchmark", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV) has been added to the Russell Small Cap Comp Value Benchmark. This update reflects the company's inclusion in important market indices, alongside several other Russell index inclusions announced on the same day. Minerva Neurosciences i", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfde8ef723", "source_name": "marketscreener.com", "published_at": "2026-06-29T16:39:34", "published_display": "29 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPSll0ZHlVRVpfLTJXZk9kdXcxOGFValIwcWFFVWVuRWJMQ2pDVkc4cFBjYm5wWnlPN0pCb0N3WGFVWmQ2bTAxY2F0STlsYTdhdzBRZmJOWnlYVFNCak0xWGtTRXh1amV2NE14NjNkaHNZT0ZDZWNBSFdkd01zZEJjZGlnTjJkMWV2aUdQRzVpUEIwN3NFUDhjTF9qSlZRZ0Z0UjZTX3BQWEVzWnFmdG04NnJ4M0EyUFVUZkJicnBkVUpqX0w1TkJlQkhxMA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000E Index", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company, has been added to the Russell 3000E Index. The company focuses on developing product candidates for central nervous system (CNS) diseases, including roluperidone for schizophrenia and MIN-30", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-3000e-index-ce7f5fdedd8ff023", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:41:36", "published_display": "29 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000 Index", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company, has been added to the Russell 3000 Index. The news, published on June 28, 2026, highlights the company's progress in developing therapies for central nervous system diseases. Minerva Neurosc", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-3000-index-ce7f5fdfdf8bf220", "source_name": "marketscreener.com", "published_at": "2026-06-29T03:39:03", "published_display": "29 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Value Benchmark", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company focused on CNS diseases, has been added to the Russell 2500 Value Benchmark. The company is currently developing roluperidone for schizophrenia and has rights to MIN-301 for Parkinson's disea", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-2500-value-benchmark-ce7f5fdfde89f620", "source_name": "marketscreener.com", "published_at": "2026-06-29T03:39:03", "published_display": "29 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000 Value Benchmark", "summary": "Minerva Neurosciences, Inc. (NasdaqCM: NERV) has been added to the Russell 3000 Value Benchmark, according to an announcement published on June 28, 2026. This inclusion indicates an updated valuation and categorization within the financial markets. The company, a clinical-stage b", "url": "https://www.marketscreener.com/news/minerva-neurosciences-inc-nasdaqcm-nerv-added-to-russell-3000-value-benchmark-ce7f5fdcd08df72d?utm_source=copy&utm_medium=social&utm_campaign=share", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T19:39:42", "published_display": "28 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Minerva Neurosciences, Inc \u2013 NASDAQ:NERV", "summary": "This article provides a financial snapshot for Minerva Neurosciences, Inc (NASDAQ: NERV), specifically highlighting its price-to-sales forward ratio. It also details navigation and product information for the TradingView platform where this data is presented. The content appears ", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:39:54", "published_display": "28 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Growth Benchmark Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxOaTN3b2hqOXJ2Wk1JT3BKUVg3LVBiSDczZXBiWVdTU2hvSVhPa29iWTR1MUFFUnBuOXF2VW4wNTVNUVc2dDNFM1QxNnlwT205VjR2R181ck5zNGhRd21oY2VSWnk4eVFPT0dFd2NQNWVxWDctdWViNTR0TkRncnBteUp5UE1JM1R0OGh4WjItc0EwSzNHWF82NzZEVUZ4UnRyT0p4RHhpNk5taHN5dGlxTzB4aUhmTktqVVdPMFhtaGpodURoMHpjM0JqQUtrN29QUTN1bmlDd2FTZ1VpSElvMW9Md1hSUFhvazRxVUNHVnktamVsZDZzMFpPSFNBWnpnTHFwOXAwVE9Lc0NLOUM2WElrNWZQQ3BmNnJwX1pzWQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOREpQNnFWZzdNVEJJVTlhQVB5WjhLa1JRd255QlR5MDFZODRxemtfLXJsbF9sVVpBc0FtcVVqa3RvSmtXQW5BME1kYjc5ZlpoUkZIdmhIejA4MVlBZmJFZnVnZmhQc2RHMTRtRXRXLWdjYUJUcmFuNy0xR3FvVDdwaXNvaWNITm5lTk05Y1FQYUFXeU1xeTlLNnNxazl2MlluMk1wM3NBRFpZUVdSVGJucEJYX0JOcE5lWWluUmIyLXdWWVQtZWFJQnA1Zw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc Actuals & Estimates (NASDAQ:NERV)", "summary": "This article provides an overview of Minerva Neurosciences, Inc. (NASDAQ: NERV) stock, covering its current price, historical performance, analyst forecasts, and financial data. It details recent movements in stock price, market capitalization, and upcoming earnings report, along", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:39", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NERV Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Minerva Neurosciences, Inc. (NERV) stock, including analyst price targets, historical performance, and financial data. Analysts estimate a maximum future price of $14.00 and a minimum of $7.00 for NERV. The company's current stock price is $4.", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T01:05:46", "published_display": "27 Jun 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc Actuals & Estimates (FWB:4MNA)", "summary": "This article provides an overview of Minerva Neurosciences Inc (FWB:4MNA) stock, including its financial actuals, analyst estimates, price forecasts, and historical price performance. It details the company's past earnings and revenue, future earnings report dates, and states tha", "url": "https://www.tradingview.com/symbols/FWB-4MNA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:10:46", "published_display": "26 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Minerva Neurosciences Inc Stocks", "summary": "This article lists ETFs that invest in Minerva Neurosciences Inc (NERV) stocks, providing details such as market value, weight, issuer, and expense ratio for each fund. It highlights the Invesco NASDAQ Future Gen 200 ETF (QQQS) as one such fund, making investing in NERV more acce", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/etfs/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-06-26T09:10:23", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Minerva Neurosciences, Inc \u2013 NASDAQ:NERV", "summary": "This article provides a brief snapshot of the \"Price to earnings forward\" metric for Minerva Neurosciences, Inc (NASDAQ: NERV) on TradingView. It indicates that the market was closed with no trades at the time of publication. The content also lists various features and financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:23", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Minerva Neurosciences, Inc \u2013 NASDAQ:NERV", "summary": "This article provides financial data for Minerva Neurosciences, Inc. (NASDAQ: NERV), specifically focusing on its forward price-to-book ratio. The content is presented within the TradingView platform, indicating it's a financial data point rather than a detailed news analysis.", "url": "https://www.tradingview.com/symbols/NASDAQ-NERV/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:46", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4MNA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Minerva Neurosciences Inc. (4MNA) stock, including analyst price targets, historical highs and lows, and upcoming earnings information. Analysts have given a 1-year price forecast up to 8.16 EUR, with a maximum estimate of 12.03 EUR and a mini", "url": "https://www.tradingview.com/symbols/SWB-4MNA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:09:51", "published_display": "25 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc (NERV) Institutional Confidence", "summary": "Minerva Neurosciences Inc (NERV) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 275.59% quarter-over-quarter to 71.95%. The largest institutional shar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nerv/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:16", "published_display": "18 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc (NERV) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Minerva Neurosciences Inc (NERV) has an earnings forecast score of 6.67, ranking 324 out of 388 in its industry, with an average analyst price target of USD 4.50. Three analysts currently rate the stock as \"Hold.\" Despite a previous quarter's EPS of -25.45, the next quarter expec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nerv/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:16", "published_display": "18 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc (NERV) Valuation: PE, PB & Fair Value Analysis", "summary": "Minerva Neurosciences Inc (NERV) currently has a valuation score of 8.70, placing it 102nd out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -0.11, significantly below its recent high and above its recent low. However, releva", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nerv/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:16", "published_display": "18 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Inc (NERV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Minerva Neurosciences Inc (NERV), focusing on its current stock price momentum, support and resistance levels, and key indicators. It highlights NERV's momentum score, its trading range, and a predominantly \"Sell\" signal based on vari", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nerv/technical", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:16", "published_display": "18 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (Nasdaq:NERV) - Stock Analysis", "summary": "Minerva Neurosciences (Nasdaq:NERV) is a clinical-stage biopharmaceutical company focused on central nervous system diseases, with its lead product candidate roluperidone in a Phase 3 confirmatory trial for negative symptoms of schizophrenia. The company faces significant risks i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nerv/minerva-neurosciences", "source_name": "Simply Wall Street", "published_at": "2026-06-08T07:09:11", "published_display": "08 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) CFO awarded 680,000 stock options at $4.6800", "summary": "Minerva Neurosciences' SVP, CFO, and Secretary, Frederick W. Ahlholm, was granted 680,000 employee stock options with an exercise price of $4.6800 per share, expiring on June 2, 2036. The options will vest 25% on June 3, 2027, with the remainder vesting in equal quarterly install", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-ea31a3d5099f.html", "source_name": "Stock Titan", "published_at": "2026-06-06T05:09:53", "published_display": "06 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences grants 50,000 options to director | NERV Insider Trading", "summary": "Minerva Neurosciences (NERV) director Inderjit Kaul was granted 50,000 stock options as equity compensation. The options have an exercise price of $4.68 per share and vest in four equal quarterly installments, beginning three months after June 3, 2026. Following this grant, Kaul ", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-d1142b17194d.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:40:19", "published_display": "05 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences director granted 50,000 options | NERV Insider Trading", "summary": "Minerva Neurosciences director G Jan Van Heek was granted 50,000 stock options with an exercise price of $4.68 per share, expiring on June 2, 2036. The options will vest in four equal quarterly installments, contingent on his continued service as a non-employee director. This tra", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-42a119fcdce0.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:40:18", "published_display": "05 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) grants director 50,000 stock options at $4.68", "summary": "Minerva Neurosciences (NERV) has granted director Fouzia Laghrissi-Thode 50,000 stock options with an exercise price of $4.68 per share. The options expire on June 2, 2036, and vest in four equal quarterly installments, contingent on her continued service as a non-employee direct", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-66e71b36737a.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:40:18", "published_display": "05 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) awards 50,000 stock options to director", "summary": "Minerva Neurosciences (NERV) has granted 50,000 stock options to director Hans Peter Hasler with an exercise price of $4.68 per share and an expiration date of June 2, 2036. The options will vest in four equal quarterly installments, contingent on his continued service as a non-e", "url": "https://www.stocktitan.net/sec-filings/NERV/form-4-minerva-neurosciences-inc-insider-trading-activity-c1d1689ea12c.html", "source_name": "Stock Titan", "published_at": "2026-06-05T21:40:18", "published_display": "05 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NERV: Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027", "summary": "Minerva Neurosciences (NERV) is developing Roluperidone as a monotherapy for primary negative symptoms in schizophrenia. The drug is currently in a robust Phase III trial, with key efficacy data anticipated in 2027. This program is strengthened by strong intellectual property and", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3480925:0-nerv-roluperidone-targets-negative-symptoms-in-schizophrenia-with-pivotal-data-expected-in-2027/", "source_name": "TradingView", "published_at": "2026-06-04T23:38:59", "published_display": "04 Jun 2026 23:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) holders approve officer shield, drop forum clause", "summary": "Minerva Neurosciences (NERV) stockholders approved significant amendments to the company's charter and bylaws at their 2026 annual meeting. Key changes include limiting officers' monetary liability as permitted by Delaware law and removing the exclusive forum provision. Stockhold", "url": "https://www.stocktitan.net/sec-filings/NERV/8-k-minerva-neurosciences-inc-reports-material-event-658c9fbabf88.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:58", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/minerva-neurosciences-establishes-scientific-advisory-200500434.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:05:00+00:00", "published_display": "01 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Establishes Scientific Advisory Board", "summary": "Minerva Neurosciences has formed a Scientific Advisory Board (SAB) to guide the development of roluperidone for negative symptoms of schizophrenia and its broader R&D pipeline. The SAB comprises distinguished experts in psychiatry and neuroscience. Roluperidone is currently in a ", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304700/0/en/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:10:07", "published_display": "01 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/know-minerva-neurosciences-nerv-rating-160003876.html", "source_name": "Zacks", "published_at": "2026-05-20T16:00:03+00:00", "published_display": "20 May 2026 16:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/minerva-neurosciences-nerv-loses-37-133503465.html", "source_name": "Zacks", "published_at": "2026-05-20T13:35:03+00:00", "published_display": "20 May 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Minerva Neurosciences (NERV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5Fbjd4bEREQlkzMWtqNlEtLUwxZGFhM2VJQTQ3TmtHS0psVWRZUmRGcWpNSDJETHRXWjhMY3pjUGlUREFCSFo5LU1MVTNvRml3MmM3SlhhRWdWeDZxNHZrTkphU19hT0o0a21ZbA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/minerva-neurosciences-participate-2026-jefferies-200500719.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T20:05:00+00:00", "published_display": "18 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva CEO to join Jefferies 2026 healthcare fireside chat June 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVy0tNElXZ0FVZ3ZsODREUmk3SjU2RVM4R1diWUxvd3dSQnZHekkzMXdqR21jRzByc0UzMlFoN1ZnS0lmLXQ2TWh3SWwzdTFhYm5fLUpwSHQ3YUxTNzduZFpTTkxFcmZ4LWZXN0F0T0tmOHJJRHJrWUdEODJ0MXZYWVZzYjJpdU02SlR2RGViZ0x4Nm1rUmRRY3l4SkpaOEFuUGRhZWFwdmFwXzJ0blI5MnRSbmZzMk02djNOSg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/minerva-neurosciences-q1-earnings-snapshot-120758716.html", "source_name": "Associated Press", "published_at": "2026-05-05T12:07:58+00:00", "published_display": "05 May 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNc1JMMHdUQTR5WE1GSGxwaFdnS3pJTU9LRGdtTkYtd2NmT0N3Y01jNURYVEtMb09kazlvZE83bHE1S2xfc0p5Si16OG1NTmFsZmU4MUJEanZGSEl6TTRxdjVOUDNvWldYUFF5MWpvTzc4LTVaLWRzR3I2c0RXZFRkUDhQa3dmb2NMaHFlZ2YzYzhVeXBEWUM4ZWF1WVE2VTAyU0VMTUUwcEpheDh3eW5nbWZfT096Zw?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva stock wins New Outperform at Citizens (NERV:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPMm5YXzRTYzA5OEl3YnJnLUZxenFtYUdYanJ4eHlNZXhFd0JNSmQ5Z29acmhjbHdhTkpYb0lKYnV2Mlc0cjUzbFhVUDl0UmpIbUZmS1VZR28yODhrYWMwM2ZOM2s3V19ZWjhMTmQxcHBaZWxIay03QVNmYUs2NHRyS0dmTVEtWUk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Announces First Patient Screened in", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wJBVV95cUxPN0hrN0JFQi11UEZMOUdmWjNUcjZfYmxBVEc5TUdIZEl5OG41TjBvb1JmT2lNamEwLTNzNHltb0ZCaDFZVjlTWDZjbnItNnEyQVp5NVdmZlk4c1oxYUZYSklJeG1PaHJVLW9QdlJoMEZsZUJJYmc0b29kbTNucXZ5c2JGVXIwaHItNkN3MnZfYm5GZU5KVTNIQ0JIUGMxQ05CU0VBNjJCb3BabE5aT3dhMzdsRm5QOEFZQkNybEE1NllZQWlpdXVfaTE4VHV4Sm9SRVdMN3BoN3lUMUZ5YkpyVlpHbGtlbDRfdmxJRWdOT2g2bXI5eUdYbmhCb1F3SVBqZ2xsZVJSb1NmekprQ185N3pQaU5CRS1oUG9tMk1vQTJkTEg1MGVlMzJTbmhtaXRxMG83YVZfWmhYMTN5Q3R1Rll0bE40THdMS0tycVp0a2pPSnJ1RXRTbjFfYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPY3pWYTZyVnJIYlcwdDkzLU1aUWFVWFVUamZzLTF0Y1l6a04xaW9mWFpkc1Jyc3ZBZFpFYXFqQ2h2VlFTNDV1RjNjUmRNcmR2MGRMT3VubGxRNWllVjNGRDlmNjVXcmpMbWtScjlFQmlMRTBscjBBdEVWenFJY0lwZjdBeWJnQThYMHMwcHJSQ1JrQzhT?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences\u2019 Unexpected Surge: Should You Invest?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOT1RqcnNBZ2dHMVp1Vk9JNVVhNTFGRl9CU3M5VVhFT2pXS2ZYMk8yZkFONTVEMWk4Qzg4c2s3elV0TFBWYTVaQnR0QkxCSWlRdVZqcTU1bGRwU0NYN2huMi1rbjNsNTh3NlJlZF9INjNGSGlyMk0ySThsUWxQZDhvYVB6VjE?oc=5", "source_name": "StocksToTrade", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Stock (NERV) Opinions on $200M Funding Deal | NERV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPVVBERVRCVXdmSWtLV3pGNXNwRkpUa3ZVcnZBUUcxaXN3Ty1UMFllelVvd3EzWlBxRVNSS2diLU9ndjZBRTgyT3gxLU5OTW9TQkVoY3JBUGVDdkVNODhlOGdKVDVxR3FkV3lXU0NmZmE0X2tUb2xVakQtbktDVk1MUWtqS1ZGSXY5dzdYbkRYSW9KUjZvV0o2YTdaaEJvTjN5R1pLUGNqZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Pr", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPN3U5M2p5Sm4tbTl5WFFrcjloUlFRYjFKMkd5RHdnY253dkVWQWR6M21QdmFHX3ZPTFkyV2dXOE00cDk0ZGVTRUN0enZGWjEtQzR2MDRXcmVoVHdpY0l6Z0Z5dlJId3ZKNF9JU1FpM0xJOEZ2N0Q5SGh2b19SRGlJTF84QUF5S0QwNVZFTkpuMG1Fc0p2d2c?oc=5", "source_name": "Market source", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosci (NERV) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5RTi1qRVJ6cTZGaUNJOGRBSXhfR0pEdm4zTmcwZWVybk03UmE2YmVIbWdyM2EwdGE5WGxILXhJMDROXzF6ano2T1otRmlYSGllNEZv?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:36:48+00:00", "published_display": "25 Apr 2025 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA hands Minerva Neurosciences refusal to file letter for its roluperidone NDA for schizophrenia", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPZGRBVGpLdWEzY2NJb09pTnRkOXdQcFdOY25nNEFLYVBnY0xNc0k5eE43aExDT1pZQVFsM0FiZXkwQ3lDcEV0RGVTOUpMMHR1a1ZNWEZaMzZ3MFRQZVZEUjJLcnVTRzV4Ml9XbEFBU0VXeWJyazlVMS1EUzZQY3ZoT3pOa2JDU2hqLWVVUzZ5RnA4cTZmS0xyZ0g0Q2d6SVBKX0sxbTZNQU92UXpZRGxmMm9NTmd1cGhTdnhDSXNONzQtZ2M2MlpmOGlpeDJJWEU?oc=5", "source_name": "drugdiscoverytrends.com", "published_at": "2022-10-20T07:00:00+00:00", "published_display": "20 Oct 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Minerva Neurosciences (NERV) Stock Price, News & Analysis $NERV", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE80XzJnYTlkN050MjZmUXFZUjR0aEMxYnM0bHlhUHFBQ3RHV3RnRkxHTldfMkw3MlhEQTJtY2JiTE9LOXd3eUNrVXlvQ2tLdktaM25MSGx5T0VsZw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-15T02:11:50+00:00", "published_display": "15 Aug 2016 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 59, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 40, "score": 55, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 21.05, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 8.05, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 2.9, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.72, "latest_week": "2026-07-10", "one_week_move": -7.5, "four_week_move": 4.7, "twelve_week_move": -29.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.829839, "market_dynamics_buy_signal": false, "relative_strength": -4.863495, "fair_value_gap": 18.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 42.4048, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.5% over one week, +4.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 7}, {"label": "marketscreener.com", "count": 6}, {"label": "TradingKey", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Zacks", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.5% over one week, +4.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neurosciences Inc"}], "updated_at": "2026-07-16T08:13:36.789281+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}